Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

EarlySense Patient Monitoring System Saw 40 Percent Increase in Adoption in 2016

XTALKS VITALS NEWS

Patient

The contact-free system was used to monitor the vital signs of over 115,000 patients in hospital facilities and home environments last year.

Share this!

January 25, 2017 | by Sarah Hand, M.Sc.

In 2016, adoption of the EarlySense continuous medical monitoring system increased by almost 40 percent, to include over 105 clinical care areas around the world. The contact-free system was used to monitor the vital signs of over 115,000 patients in hospital facilities and home environments last year.

According to statistically analysis conducted by EarlySense, the company estimates that their monitoring system may have helped save more than 550 lives, and prevent 800 falls and over 45,000 hospitalization days. In the absence of EarlySense monitoring and alerts, these events would cost a combined $30 million.

“In 2016, EarlySense significantly expanded the reach and impact of our hospital-proven technology and we are pleased to achieve these milestones,” said Avner Halperin, Founder and CEO of EarlySense. “Almost daily we hear from medical institutions about how they saved a life or dramatically improved a patient's outcome by leveraging EarlySense – it is extremely rewarding. It is clear that continuous monitoring is poised to become a global standard of care, and we look forward to providing valuable health insight and support to facilities, health teams and patients in 2017 and beyond.”



EarlySense has since made some upgrades to it continuous monitoring medical devices. The company launched InSight, a product aimed at reducing patient falls and hospital admissions in nursing facilities. A new Multi-Parameter Alert was also introduced, which monitors a patient’s heart and breathing rates to help healthcare providers in the early detection of sepsis.

“Non-ICU patients are at risk for a variety of complications during hospitalization and early warning signs are often subtle and not easily detected,” said Halperin. “By providing healthcare professionals with continuous data and timely indication of change through our Multi-Parameter Alert, precious time can be saved enabling early detection and treatment of sepsis as well as other potential adverse events.”

EarlySense is also breaking into the consumer health space by introducing its LIVE health monitoring solution. LIVE is primarily a sleep monitor, which EarlySense claims is the first consumer health monitoring product to be based on medically-proven technology.


Keywords: Patient Monitoring, Medical Device, Healthcare


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
New Self-Injectable Form of Lupus Drug Approved by the FDA

July 25, 2017 - Patients with systemic lupus erythematosus (SLE) will now have the option to self-inject their medication thanks to the FDA approval of GSK’s reformulated lupus drug, Benlysta (belimumab).

Featured In: Biotech News


Canadian Chicken Farmers to Further Reduce Use of Antibiotics

July 24, 2017 - The Chicken Farmers of Canada, a national group dedicated to supporting poultry farmers and helping them meet consumer demand for chicken, has announced their strategy for eliminating the use of certain antimicrobials in meat production.

Featured In: Food News


Neonatal MRI Medical Device Approved by the FDA

July 24, 2017 - Medical device maker Aspect Imaging has received US Food and Drug Administration (FDA) approval for its Embrace Neonatal MRI System.

Featured In: Medical Device News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

Top 5 Most Impactful Tweets from #AAIC17

REGISTER FOR THESE WEBINARS

Into the Great Wide Open: PTC’s Transformation & Global Journey to Bring Patients a First Ever Rare Disease Therapy


EDC and eSource: Combined for Better Data and Faster Insights


Using Model Reduction to Bridge the Quality Systems Pharmacology-Pharmacometrics Divide


How to Maximize Your Non-GLP Toxicology Studies: A Guide for Optimal Design and Methodology


Copyright © 2016-2017 Honeycomb Worldwide Inc.